Johnson & Johnson Recalls More Medications for Defective Packaging

Johnson & Johnson is on the hot seat again after its consumer-products division recalled 12 million bottles of Mylanta and almost 85,000 bottles of AlternaGel liquid antacid because of a product defect. In this recall, there was a small amount of alcohol not noted on a package which came from the flavoring agent and amounts to less than 1%.

According to a Reuters article, the brands were manufactured in a joint venture with Merck & Co. at a plant in Lancaster, Pennsylvania, a different plant from the J & J plant closed in Fort Washington, Pennsylvania after millions of bottles of children’s cold and allergy medications were found to have inconsistent formulations and contamination.

Just last week, J & J recalled 9 million bottles of Tylenol because of the alcohol problem.
So far this year, more than 200 million of J & J products have been recalled including Tylenol and Motrin, Benadryl, and Rolaids. Sales dropped 25% and company executives had to testify to Congress about the lack of quality control. And the problem has not just been a domestic one. J & J’s plant in Las Piedras, Puerto Rico, also had a contamination problem that FDA investigators say still is not fixed. That plant produces most of the over-the-counter drugs sold by J & J’s McNeil Consumer Healthcare division.

While you chances of getting sick from the inconsistent formulations and alcohol are remote, the FDA went out on a limb and even suggested the public choose generics over the risky J & J or McNeil brands. If you or a loved one is sickened by a defective pharmaceutical, you may have questions whether the responsible party can be held liable for a medication that contains bacterial contamination or an inconsistent amount of active ingredient. Those are questions for the Jacksonville product liability attorneys at Farah & Farah.